Sökning: onr:"swepub:oai:DiVA.org:uu-474197" >
Advances in the dev...
Advances in the development of new biomarkers for Alzheimer's disease
-
- Klyucherev, Timofey O. (författare)
- Uppsala universitet,Schiöth: Funktionell farmakologi,IM Sechenov First Moscow State Med Univ, Inst Pharm, Dept Pharmacol, Moscow, Russia.
-
- Olszewski, Pawel K. (författare)
- Uppsala universitet,Schiöth: Funktionell farmakologi
-
- Shalimova, Alena (författare)
- Uppsala universitet,Schiöth: Funktionell farmakologi,IM Sechenov First Moscow State Med Univ, Inst Pharm, Dept Pharmacol, Moscow, Russia.
-
visa fler...
-
- Chubarev, Vladimir N. (författare)
- IM Sechenov First Moscow State Med Univ, Inst Translat Med & Biotechnol, Moscow, Russia.
-
- Tarasov, Vadim V. (författare)
- IM Sechenov First Moscow State Med Univ, Inst Pharm, Dept Pharmacol, Moscow, Russia.;IM Sechenov First Moscow State Med Univ, Inst Translat Med & Biotechnol, Moscow, Russia.
-
- Attwood, Misty M. (författare)
- Uppsala universitet,Schiöth: Funktionell farmakologi
-
- Syvänen, Stina (författare)
- Uppsala universitet,Geriatrik
-
- Schiöth, Helgi B. (författare)
- Uppsala universitet,Schiöth: Funktionell farmakologi
-
visa färre...
-
(creator_code:org_t)
- 2022-04-21
- 2022
- Engelska.
-
Ingår i: Translational Neurodegeneration. - : Springer Nature. - 2047-9158. ; 11:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most common type of neurodegenerative dementia. The prevalence of AD is expected to increase as the population ages, placing an additional burden on national healthcare systems. There is a large need for new diagnostic tests that can detect AD at an early stage with high specificity at relatively low cost. The development of modern analytical diagnostic tools has made it possible to determine several biomarkers of AD with high specificity, including pathogenic proteins, markers of synaptic dysfunction, and markers of inflammation in the blood. There is a considerable potential in using microRNA (miRNA) as markers of AD, and diagnostic studies based on miRNA panels suggest that AD could potentially be determined with high accuracy for individual patients. Studies of the retina with improved methods of visualization of the fundus are also showing promising results for the potential diagnosis of the disease. This review focuses on the recent developments of blood, plasma, and ocular biomarkers for the diagnosis of AD.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- Alzheimer's disease
- Amyloid beta peptides
- Biomarkers
- Blood
- Cytokines
- Inflammation
- MicroRNA
- Ocular biomarkers
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas